To confirm these findings, the PROSPECT-C phase II study was carried out to track the clonal evolution of resistant subclones using ctDNA during EGFR antibody therapy in patients with RAS-wildtype (WT) CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.